Aspire Biopharma
ASBP
23 hedge funds and large institutions have $646K invested in Aspire Biopharma in 2025 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
64% more funds holding
Funds holding: 14 → 23 (+9)
19% more capital invested
Capital invested by funds: $545K → $646K (+$101K)
0% more ownership
Funds ownership: 0% → 0.01% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$179K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$104K |
| 3 |
AC
Antara Capital
New York
|
+$84.6K |
| 4 |
CA
Crewe Advisors
Salt Lake City,
Utah
|
+$78.1K |
| 5 |
RA
Resolute Advisors
San Francisco,
California
|
+$34.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Procyon Advisors
Shelton,
Connecticut
|
-$73.1K |
| 2 |
Jane Street
New York
|
-$51.6K |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$10.5K |
| 4 |
Goldman Sachs
New York
|
-$5.03K |
| 5 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
-$4.44K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Goldman Sachs
New York
| – | -$5.03K | -16 | Closed |
|
|
SRL
27
Scientech Research LLC
Jersey City,
New Jersey
| – | -$4.44K | -14 | Closed |
|
28
Raymond James Financial
St Petersburg,
Florida
| – | -$673 | -2 | Closed |
|
ASBP Hedge Fund Activity: Q3 2025 in Review
23 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q3 2025, worth a combined $646K — up 19% from $545K a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ASBP positions and 3 closed out — a net gain of 9 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $179K. The largest seller was Procyon Advisors, cutting an estimated $73.1K.
- 23 institutional investors held Aspire Biopharma (ASBP) as of Q3 2025, up from 14 in Q2 2025.
- Funds reported $646K of Aspire Biopharma stock for Q3 2025, up 19% quarter-over-quarter.
- 12 funds opened new Aspire Biopharma positions in Q3 2025 and 3 closed out, a net change of +9 holders.
- The largest Aspire Biopharma buyer in Q3 2025 was Vanguard Group, an estimated $179K added.
- The largest Aspire Biopharma seller in Q3 2025 was Procyon Advisors, an estimated $73.1K sold.
Based on aggregated 13F filings for Q3 2025.